amantadine has been researched along with Disease Models, Animal in 66 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pilocarpine-induced status epilepticus (SE), which results in the development of spontaneous recurrent seizures (SRSs) activates glutamatergic receptors that contribute to seizure sustenance and neuronal cell death." | 7.91 | Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. ( Mohammad, H; Moien-Afshari, F; Sekar, S; Taghibiglou, C; Wei, Z, 2019) |
| "This study sought to investigate the in vivo antiviral effect of amantadine (AM) and biphenyl dimethyl dicarboxylate (DDB) on hepatitis B virus (HBV) in HBV replication mice." | 7.80 | [Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice]. ( Jiang, Z; Liu, F; Meng, H; Shi, Y; Yu, Y; Zhou, Q, 2014) |
| "Pilocarpine-induced status epilepticus (SE), which results in the development of spontaneous recurrent seizures (SRSs) activates glutamatergic receptors that contribute to seizure sustenance and neuronal cell death." | 3.91 | Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. ( Mohammad, H; Moien-Afshari, F; Sekar, S; Taghibiglou, C; Wei, Z, 2019) |
| "This study sought to investigate the in vivo antiviral effect of amantadine (AM) and biphenyl dimethyl dicarboxylate (DDB) on hepatitis B virus (HBV) in HBV replication mice." | 3.80 | [Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice]. ( Jiang, Z; Liu, F; Meng, H; Shi, Y; Yu, Y; Zhou, Q, 2014) |
| "Amantadine treatment also reduces the production of NO and metabolism of GABA." | 1.56 | Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways. ( Garg, C; Garg, M; Walia, V, 2020) |
| "Amantadine (10 mg/kg PO) was tested as a positive control." | 1.56 | The selective 5-HT ( Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A, 2020) |
| "Metformin is a medication that is widely prescribed for the management of type 2 diabetes." | 1.48 | Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease. ( Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK, 2018) |
| "Spinocerebellar ataxias are autosomal dominant diseases, associated in some types with a CAG repeat expansion, and characterised by a progressive loss of motor function." | 1.39 | Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. ( Nag, N; Storey, E; Tarlac, V, 2013) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "Amantadine was effective at 10, 30, and 100mg/kg/day, rimantadine was protective at 10 and 30mg/kg/day (highest dose tested), and ribavirin was active at 30 and 75mg/kg/day, with survival ranging from 60-100% for oral treatments initiated at -2h." | 1.38 | Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. ( Gross, M; Julander, JG; Nguyen, J; Smee, DF; Tarbet, EB, 2012) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Amantadine has also revered molindone-induced inhibition of traction response in mice." | 1.31 | Effects of amantadine on modification of dopamine dependent behaviours by molindone. ( Balsara, JJ; Chandorkar, AG; Dhaware, BS; Nandal, NV, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (15.15) | 18.7374 |
| 1990's | 1 (1.52) | 18.2507 |
| 2000's | 20 (30.30) | 29.6817 |
| 2010's | 25 (37.88) | 24.3611 |
| 2020's | 10 (15.15) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Turcu, AL | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Pérez, B | 1 |
| Soto, D | 1 |
| Sureda, FX | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Vázquez, S | 1 |
| Lazarova, M | 1 |
| Tancheva, L | 1 |
| Chayrov, R | 1 |
| Tzvetanova, E | 1 |
| Alexandrova, A | 1 |
| Popatanasov, A | 1 |
| Uzunova, D | 1 |
| Stefanova, M | 1 |
| Stankova, I | 1 |
| Kalfin, R | 1 |
| Calderón, VM | 1 |
| Luna-Leal, A | 1 |
| Gómez-Paz, A | 1 |
| Ramírez-López, F | 1 |
| Arias-García, M | 1 |
| Lara-González, E | 1 |
| Galarraga, E | 1 |
| Bargas, J | 1 |
| Cohen, SR | 1 |
| Terry, ML | 1 |
| Coyle, M | 1 |
| Wheelis, E | 1 |
| Centner, A | 1 |
| Smith, S | 1 |
| Glinski, J | 1 |
| Lipari, N | 1 |
| Budrow, C | 1 |
| Manfredsson, FP | 1 |
| Bishop, C | 1 |
| Murakami, Y | 1 |
| Nishijima, H | 1 |
| Nakamura, T | 1 |
| Furukawa, T | 1 |
| Kinoshita, I | 1 |
| Kon, T | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Egan, T | 1 |
| Clark, I | 1 |
| Vissel, B | 1 |
| Vaz, RL | 1 |
| Sousa, S | 1 |
| Chapela, D | 1 |
| van der Linde, HC | 1 |
| Willemsen, R | 1 |
| Correia, AD | 1 |
| Outeiro, TF | 1 |
| Afonso, ND | 1 |
| Walia, V | 1 |
| Garg, C | 1 |
| Garg, M | 1 |
| Depoortere, R | 1 |
| Johnston, TH | 2 |
| Fox, SH | 2 |
| Brotchie, JM | 3 |
| Newman-Tancredi, A | 1 |
| Ryu, YK | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Choi, DH | 1 |
| Kim, YH | 1 |
| Hwang, JH | 1 |
| Noh, JR | 1 |
| Lee, TG | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Loiodice, S | 1 |
| Denibaud, AS | 1 |
| Deffains, W | 1 |
| Alix, M | 1 |
| Montagne, P | 1 |
| Seffals, M | 1 |
| Drieu La Rochelle, C | 1 |
| Mohammad, H | 1 |
| Sekar, S | 1 |
| Wei, Z | 1 |
| Moien-Afshari, F | 1 |
| Taghibiglou, C | 1 |
| Bleimeister, IH | 1 |
| Wolff, M | 1 |
| Lam, TR | 1 |
| Brooks, DM | 1 |
| Patel, R | 1 |
| Cheng, JP | 1 |
| Bondi, CO | 1 |
| Kline, AE | 1 |
| Sulkowski, G | 1 |
| Dąbrowska-Bouta, B | 1 |
| Strużyńska, L | 1 |
| Tronci, E | 2 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 3 |
| Ko, WK | 1 |
| Pioli, E | 1 |
| Li, Q | 2 |
| McGuire, S | 1 |
| Dufour, A | 1 |
| Sherer, TB | 1 |
| Bezard, E | 3 |
| Facheris, MF | 1 |
| Sutton, TC | 1 |
| Obadan, A | 1 |
| Lavigne, J | 1 |
| Chen, H | 1 |
| Perez, DR | 1 |
| Liu, F | 1 |
| Jiang, Z | 1 |
| Zhou, Q | 1 |
| Yu, Y | 1 |
| Meng, H | 1 |
| Shi, Y | 1 |
| Ikeda, J | 1 |
| Kojima, N | 1 |
| Saeki, K | 1 |
| Ishihara, M | 1 |
| Takayama, M | 1 |
| Bortolanza, M | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| Dos-Santos-Pereira, M | 1 |
| da-Silva, CA | 1 |
| Del-Bel, E | 1 |
| Vonder Haar, C | 1 |
| Lam, FC | 1 |
| Adams, WK | 1 |
| Riparip, LK | 1 |
| Kaur, S | 1 |
| Muthukrishna, M | 1 |
| Rosi, S | 1 |
| Winstanley, CA | 1 |
| Griffin, S | 1 |
| Trowbridge, R | 1 |
| Thommes, P | 1 |
| Parry, N | 1 |
| Rowlands, D | 1 |
| Harris, M | 1 |
| Bright, H | 1 |
| Titova, E | 1 |
| Ostrowski, RP | 1 |
| Zhang, JH | 1 |
| Tang, J | 1 |
| Smee, DF | 3 |
| Hurst, BL | 1 |
| Wong, MH | 1 |
| Bailey, KW | 1 |
| Morrey, JD | 1 |
| Ikeda, K | 1 |
| Yoshikawa, S | 1 |
| Kurokawa, T | 1 |
| Yuzawa, N | 1 |
| Nakao, K | 1 |
| Mochizuki, H | 1 |
| Khasanova, DR | 1 |
| Saĭkhunov, MV | 1 |
| Kitaeva, EA | 1 |
| Khafiz'ianova, RKh | 1 |
| Islaamov, RR | 1 |
| Demin, TV | 1 |
| Spinnewyn, B | 2 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 2 |
| Auguet, M | 2 |
| Lee, MJ | 2 |
| Wang, K | 1 |
| Kim, IS | 1 |
| Lee, BH | 1 |
| Han, HS | 2 |
| Adamson, AL | 1 |
| Chohan, K | 1 |
| Swenson, J | 1 |
| LaJeunesse, D | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 2 |
| Nepoklonov, AV | 2 |
| Kokshenev, II | 2 |
| Voronina, TA | 3 |
| Val'dman, EA | 3 |
| Kobylecki, C | 1 |
| Hill, MP | 2 |
| Crossman, AR | 2 |
| Ravenscroft, P | 2 |
| Kim, JH | 1 |
| Lee, HW | 1 |
| Hwang, J | 1 |
| Kim, J | 1 |
| Lee, WH | 1 |
| Suk, K | 1 |
| Nguyen, JT | 1 |
| Barnard, DL | 1 |
| Julander, JG | 2 |
| Gross, M | 2 |
| de Jong, MD | 1 |
| Went, GT | 1 |
| Nag, N | 1 |
| Tarlac, V | 1 |
| Storey, E | 1 |
| Tarbet, EB | 1 |
| Nguyen, J | 1 |
| Kotel'nikova, SO | 1 |
| Kraĭneva, VA | 1 |
| Garibova, TL | 1 |
| Aron Badin, R | 1 |
| Gaillard, MC | 1 |
| Jan, C | 1 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Brouillet, E | 1 |
| Hantraye, P | 1 |
| Pioli, EY | 1 |
| Porras, G | 1 |
| Björklund, A | 1 |
| Shinjoh, M | 1 |
| Yoshikawa, T | 1 |
| Li, Y | 1 |
| Shiraishi, K | 1 |
| Ueki, H | 1 |
| Nerome, K | 1 |
| Kamitani, W | 1 |
| Tomonaga, K | 1 |
| Ikuta, K | 1 |
| Block, F | 1 |
| Habermeyer, B | 1 |
| Herlocher, ML | 1 |
| Truscon, R | 1 |
| Fenton, R | 1 |
| Klimov, A | 1 |
| Elias, S | 1 |
| Ohmit, SE | 1 |
| Monto, AS | 1 |
| Michel, A | 1 |
| Grimée, R | 1 |
| Klitgaard, H | 1 |
| Avakian, GN | 1 |
| Nerobkova, LN | 1 |
| Katunina, EA | 1 |
| Samoĭlova, EV | 1 |
| Allers, KA | 1 |
| Bergstrom, DA | 1 |
| Ghazi, LJ | 1 |
| Kreiss, DS | 1 |
| Walters, JR | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Sova, P | 1 |
| Mistr, A | 1 |
| Kroutil, A | 1 |
| Zak, F | 1 |
| Pouckova, P | 1 |
| Zadinova, M | 1 |
| Bibbiani, F | 1 |
| Oh, JD | 1 |
| Kielaite, A | 1 |
| Collins, MA | 1 |
| Smith, C | 1 |
| Chase, TN | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Becker, PD | 1 |
| Bertot, GM | 2 |
| Souss, D | 1 |
| Ebensen, T | 1 |
| Guzmán, CA | 1 |
| Grinstein, S | 2 |
| Restelli, MA | 1 |
| Galanternik, L | 1 |
| Aranibar Urey, RC | 1 |
| Valvano, MA | 1 |
| Ilyushina, NA | 1 |
| Govorkova, EA | 1 |
| Russell, CJ | 1 |
| Hoffmann, E | 1 |
| Webster, RG | 1 |
| Lee, MG | 1 |
| Kim, KH | 1 |
| Park, KY | 1 |
| Kim, JS | 1 |
| Dhaware, BS | 1 |
| Balsara, JJ | 1 |
| Nandal, NV | 1 |
| Chandorkar, AG | 1 |
| Glasgow, LA | 1 |
| Fenton, RJ | 1 |
| Bessell, C | 1 |
| Spilling, CR | 1 |
| Potter, CW | 1 |
| Mori, K | 1 |
| Fujita, Y | 1 |
| Shimabukuro, H | 1 |
| Ito, M | 1 |
| Handa, H | 1 |
| Johannes, RS | 1 |
| Sever, JL | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Haller, O | 1 |
| Nair, KG | 1 |
| Umali, T | 1 |
| Potts, J | 1 |
| Velkov, VA | 1 |
| Stern, P | 1 |
| Srebocan, S | 1 |
| Cvetnić, S | 1 |
| Brmalj, V | 1 |
| McFadzean, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.[NCT00632762] | Phase 4 | 80 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amantadine and Disease Models, Animal
| Article | Year |
|---|---|
[Borna disease virus infection].
Topics: Amantadine; Animals; Antibodies, Viral; Antiviral Agents; Borna Disease; Borna disease virus; Brain; | 2003 |
[Glutamate antagonists for treatment of neuropathic pain].
Topics: Amantadine; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Ketamine; Me | 2003 |
Subacute sclerosing panencephalitis.
Topics: Adolescent; Adult; Amantadine; Animals; Antimetabolites; Child; Child, Preschool; Cricetinae; Diseas | 1975 |
Advances in the chemotherapy of viral diseases.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Humans; Idoxuridine; Models, Biologic | 1969 |
1 trial available for amantadine and Disease Models, Animal
| Article | Year |
|---|---|
[Amantadine sulfate (PK-Merz) in the treatment of ischemic stroke: a clinical-experimental study].
Topics: Aged; Aged, 80 and over; Amantadine; Animals; Blotting, Western; Calcium Channel Blockers; Conscious | 2009 |
61 other studies available for amantadine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.
Topics: Acetylcholinesterase; Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Male; Model | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Anim | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitat | 2022 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; D | 2020 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Ne | 2020 |
Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways.
Topics: Amantadine; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain; Diazepam; Disease Models | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levo | 2020 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ma | 2018 |
Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior Rating Scale; Behavior, Animal; Disease Models, | 2018 |
Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus.
Topics: Amantadine; Animals; Astrocytes; Behavior, Animal; Caspase 3; Cell Survival; Cognition Disorders; Di | 2019 |
Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury.
Topics: Amantadine; Animals; Brain Injuries, Traumatic; Cognition; Disease Models, Animal; Environment; Male | 2019 |
Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors.
Topics: Amantadine; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory | 2013 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Respon | 2014 |
Genome rearrangement of influenza virus for anti-viral drug screening.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Female; | 2014 |
[Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice].
Topics: Amantadine; Animals; Antiviral Agents; Dioxoles; Disease Models, Animal; DNA Replication; DNA, Viral | 2014 |
Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia.
Topics: Amantadine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blo | 2015 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Amantadine; Amphetamine; Animals; Atomoxetine Hydrochlo | 2016 |
Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo.
Topics: Amantadine; Animals; Antiviral Agents; Callithrix; Cell Line; Disease Models, Animal; Drug Design; G | 2008 |
Effect of amantadine sulphate on intracerebral hemorrhage-induced brain injury in rats.
Topics: Amantadine; Animals; Brain Edema; Brain Injuries; Cerebral Hemorrhage; Collagenases; Disease Models, | 2008 |
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Interactions; Drug Re | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Lev | 2009 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Apoptosis; Brain; Cell Count; Dis | 2012 |
A Drosophila model for genetic analysis of influenza viral/host interactions.
Topics: Amantadine; Animals; Animals, Genetically Modified; Antiviral Agents; Cell Line; Cell Membrane; Dise | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dop | 2011 |
Microglia-inhibiting activity of Parkinson's disease drug amantadine.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Cell Line | 2012 |
Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Topics: Amantadine; Animals; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Dogs; Drug Combinati | 2012 |
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype | 2013 |
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Influ | 2012 |
[Comparative study of himantane and amantadine effects in experimental intracerebral posttraumatic hematoma].
Topics: Adamantane; Amantadine; Animals; Antiparkinson Agents; Cerebral Hemorrhage, Traumatic; Disease Model | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Prophylaxis and treatment of influenza encephalitis in an experimental mouse model.
Topics: Amantadine; Animals; Antibodies, Viral; Antiviral Agents; Brain; Disease Models, Animal; Dogs; Encep | 2002 |
Assessment of development of resistance to antivirals in the ferret model of influenza virus infection.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guan | 2003 |
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug | 2004 |
[Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].
Topics: Aged; Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Electromyography; Female; Humans | 2004 |
MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amantadine; Animals; Disease Models, Animal; Dizocilpine Maleate; Male; Neurons; | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
Topics: Adenocarcinoma; Administration, Oral; Amantadine; Animals; Antineoplastic Agents; Disease Models, An | 2005 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease | 2005 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.
Topics: Adhesins, Bacterial; Adjuvants, Immunologic; Administration, Intranasal; Amantadine; Animals; Antibo | 2007 |
Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Amantadine; Animals; Antibodies, Bacterial; Bact | 2007 |
Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus.
Topics: Amantadine; Amino Acid Substitution; Animals; Antiviral Agents; Blood; Brain; Cell Line; Chick Embry | 2007 |
Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.
Topics: Adaptation, Physiological; Amantadine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; | 1996 |
Effects of amantadine on modification of dopamine dependent behaviours by molindone.
Topics: Amantadine; Animals; Behavior, Animal; Blepharoptosis; Catalepsy; Disease Models, Animal; Dopamine; | 2000 |
Advantages and limitations of animal models in the evaluation of antiviral substances.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; | 1976 |
The effects of peroral or local aerosol administration of 1-aminoadamantane hydrochloride (amantadine hydrochloride) on influenza infections of the ferret.
Topics: Administration, Oral; Aerosols; Amantadine; Animals; Carnivora; Disease Models, Animal; Ferrets; Hem | 1977 |
Some considerations for treatment of spasmodic torticollis. Clinical and experimental studies.
Topics: Amantadine; Animals; Biogenic Amines; Catecholamines; Cats; Caudate Nucleus; Disease Models, Animal; | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Anta | 1975 |
A mouse hepatotropic variant of influenza virus.
Topics: Adaptation, Physiological; Amantadine; Animals; Antigens, Viral; Cricetinae; Disease Models, Animal; | 1975 |
Ribonucleic acid (RNA) polymerase and adenyl cyclase in cardiac hypertrophy and cardiomyopathy.
Topics: Adenylyl Cyclases; Amantadine; Animals; Aorta; Cardiomegaly; Cricetinae; Disease Models, Animal; DNA | 1973 |
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amantadine; Animals; Brain; Brain Chemistry; Dise | 1974 |
[Epidemic tremor in chickens as a model for the testing of antiparkinson drugs].
Topics: Amantadine; Animals; Antiparkinson Agents; Chickens; Dihydroxyphenylalanine; Disease Models, Animal; | 1973 |